We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Blood Test May Reduce Invasive Surgeries for Bladder Cancer

By LabMedica International staff writers
Posted on 28 Apr 2023

One of the methods for treating bladder cancer involves the use of chemotherapy and/or radiation therapy, followed by a radical cystectomy only for patients who do not achieve a complete response. Those who do achieve a complete response are closely monitored following chemotherapy and/or radiation and undergo radical cystectomy if cancer reoccurs. However, radical cystectomy is a significant operation that necessitates urinary diversion, leading to life-altering consequences. Now, a new blood test may enable bladder cancer patients to avoid a precautionary cystectomy after immunotherapy treatment.

Scientists at the Netherlands Cancer Institute (NKI, Amsterdam, Netherlands) in collaboration with Inivata (Cambridge, UK) have demonstrated that a novel technique can improve the prediction of tumor recurrence. In the study, the scientists examined the blood of bladder cancer patients who had undergone immunotherapy. These patients were part of a high-risk group with an increased likelihood of disease recurrence, placing them on a waiting list for bladder removal surgery as a preventive measure. The scientists analyzed the freely circulating DNA in the patients' blood: small DNA fragments that travel through the bloodstream, which can sometimes contain mutated DNA from a tumor. The researchers investigated whether they could detect tumor DNA in these patients and use these findings to predict the likelihood of tumor recurrence.


Image: Fewer surgeries may be needed for bladder cancer due to new blood test (Photo courtesy of Freepik)
Image: Fewer surgeries may be needed for bladder cancer due to new blood test (Photo courtesy of Freepik)

The study's results were encouraging. In most cases, the researchers were able to accurately predict patients' recovery after immunotherapy based on the blood test findings. Small mutated DNA fragments from the tumor were often present in patients who did not respond well to the therapy. In contrast, no tumor DNA was detected in the blood of patients who responded positively to the immunotherapy. This latter group also experienced significantly fewer tumor recurrences. This breakthrough is crucial because cystectomies are highly invasive. There are instances where no tumor cells are detected during surgery, suggesting that the procedure might not have been necessary.

"We seem to be able to predict the course of bladder cancer with great precision using this technique," said principal investigator Michiel van der Heijden.. "That might help prevent radical surgery for a number of patients. Patients whose blood no longer contains tumor DNA may no longer need surgery at all.”

Related Links:
NKI 
Inivata 


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Incubator
HettCube 120
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit

Latest Molecular Diagnostics News

Single Metagenomic Next-Generation Sequencing Test Can Detect All Infectious Pathogens

Cutting-Edge Diagnostic Tool Rapidly Identifies Emerging SARS-CoV-2 Variants

Novel Method Analyzes Genetic Variations in Families with High Incidence of Breast Cancer